Breaking
RAPS Euro Convergence: Top Regulatory Insights - Day 1European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1
🇺🇸 FDA

Lung Cancer

Page 1 • 1 item

Gain critical insights into global lung cancer drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.

FDA Accelerated Approval of KRAS G12C Inhibitors in NSCLC: Sotorasib vs Adagrasib
AnalysisoncologyApr 25, 2026

FDA Accelerated Approval of KRAS G12C Inhibitors in NSCLC: Sotorasib vs Adagrasib

This article delves into the FDA's accelerated approval of KRAS G12C inhibitors, Sotorasib and Adagrasib, highlighting their impact on NSCLC treatment.

James Chen, PharmD